Doxifluridine (5'-dFUrd) in patients with advanced colorectal carcinoma. A phase II study.
Infusion of 5'-dFUrd (2.0-3.0 g/m2 over 1 h on days 1-5 every 3rd week) resulted in one partial response in 21 patients with advanced and progressing colorectal cancer. No patient had received chemotherapy before the 5'-dFUrd trial. Hematological and gastrointestinal toxicity were generally mild. In 4 patients peripheral neurotoxicity was diagnosed during treatment, whereas transient cerebellopathy was observed in one. Cardiac side effects (repeated angina pectoris following 5'-dFUrd infusion) led to discontinuation of treatment after two courses in one patient. It is concluded that 5'-dFUrd at the above doses is not superior to conventional 5-FU treatment in colorectal cancer. Neurological and cardiac side effects are rare but may be a problem in individual patients.
Fosså
S D
SD
Dahl
O
O
Hoel
R
R
Heier
M
M
Loeb
M
M
D000787:Angina Pectoris / Q000139:chemically induced; D001927:Brain Diseases / Q000139:chemically induced; D002272:Carcinoembryonic Antigen / Q000032:analysis; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D004576:Electromyography; D005260:Female; D005467:Floxuridine / Q000009:adverse effects / Q000627:therapeutic use*; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D012004:Rectal Neoplasms / Q000188:drug therapy*
D002272:Carcinoembryonic Antigen; D005467:Floxuridine; D005472:Fluorouracil